Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab.
Angiogenesis Inhibitors
/ therapeutic use
Diabetic Retinopathy
/ diagnosis
Female
Fluorescein Angiography
Humans
Intravitreal Injections
Leukocyte Count
Lymphocytes
/ pathology
Macular Edema
/ diagnosis
Male
Middle Aged
Neutrophils
/ pathology
Prognosis
Ranibizumab
/ therapeutic use
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
/ physiology
Diabetic retinopathy
Macular edema
Neutrophil–lymphocyte ratio
Predictors
Prognosis
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
27 Aug 2019
27 Aug 2019
Historique:
received:
27
04
2019
accepted:
15
08
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
28
12
2019
Statut:
epublish
Résumé
To investigate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients with diabetic macular edema (DME) treated monthly with ranibizumab. We retrospectively analyzed the medical records of all patients who received intravitreal ranibizumab (IVR) treatment for DME at the First Affiliated Hospital of Nanchang University between December 2015 and December 2017. Clinicopathological parameters, including NLR, were evaluated to identify predictors of better outcomes of IVR monotherapy. Ninety-one treatment-naïve eyes treated with IVR for DME were retrospectively analyzed in this study. Baseline best-corrected visual acuity (BCVA), neutrophils, NLR, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were negatively correlated with the changes in BCVA at 24 weeks compared with the baseline, while baseline central retinal thickness and lymphocytes were positively correlated with the changes in BCVA at 24 weeks compared with the baseline. Multiple linear regression analysis revealed that NLR was independently associated with the mean change of BCVA between baseline and week 24. In addition, patients with NLR < 2.27 showed a better improvement in letter score than those with NLR > 2.27. Pretreatment NLR is independently associated with the BCVA in DME patients treated with IVR, and higher pretreatment NLR may contribute to inferior BCVA outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients with diabetic macular edema (DME) treated monthly with ranibizumab.
METHODS
METHODS
We retrospectively analyzed the medical records of all patients who received intravitreal ranibizumab (IVR) treatment for DME at the First Affiliated Hospital of Nanchang University between December 2015 and December 2017. Clinicopathological parameters, including NLR, were evaluated to identify predictors of better outcomes of IVR monotherapy.
RESULTS
RESULTS
Ninety-one treatment-naïve eyes treated with IVR for DME were retrospectively analyzed in this study. Baseline best-corrected visual acuity (BCVA), neutrophils, NLR, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were negatively correlated with the changes in BCVA at 24 weeks compared with the baseline, while baseline central retinal thickness and lymphocytes were positively correlated with the changes in BCVA at 24 weeks compared with the baseline. Multiple linear regression analysis revealed that NLR was independently associated with the mean change of BCVA between baseline and week 24. In addition, patients with NLR < 2.27 showed a better improvement in letter score than those with NLR > 2.27.
CONCLUSION
CONCLUSIONS
Pretreatment NLR is independently associated with the BCVA in DME patients treated with IVR, and higher pretreatment NLR may contribute to inferior BCVA outcomes.
Identifiants
pubmed: 31455273
doi: 10.1186/s12886-019-1200-4
pii: 10.1186/s12886-019-1200-4
pmc: PMC6712590
doi:
Substances chimiques
Angiogenesis Inhibitors
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
194Subventions
Organisme : National Natural Science Foundation of China
ID : 81760179, 81360151
Organisme : Natural Science Foundation of Jiangxi Province
ID : 20171BAB205046
Organisme : Key Foundation of Education Department of Jiangxi Province
ID : GJJ160033
Organisme : Health Development Planning Commission Science Foundation of Jiangxi Province
ID : 20185118
Organisme : Jiangxi Provincial Department of Science and Technology
ID : 20141BBG70027
Références
Surv Ophthalmol. 2009 Jan-Feb;54(1):1-32
pubmed: 19171208
Ophthalmology. 2012 Apr;119(4):789-801
pubmed: 22330964
J Hepatol. 2013 Jan;58(1):58-64
pubmed: 22925812
Diabetes Technol Ther. 2013 Nov;15(11):942-7
pubmed: 23919588
BMC Med. 2013 Aug 21;11:184
pubmed: 23962071
Br J Cancer. 2013 Oct 1;109(7):1755-9
pubmed: 24008663
Diabetes Technol Ther. 2014 Aug;16(8):524-30
pubmed: 24455985
Am J Ophthalmol. 2014 May;157(5):960-70
pubmed: 24531025
Eur Urol. 2014 Dec;66(6):1157-64
pubmed: 24630414
Br J Cancer. 2014 May 13;110(10):2524-30
pubmed: 24675383
JAMA. 2014 Jun 11;311(22):2269-70
pubmed: 24915254
J Diabetes Complications. 2015 Mar;29(2):245-9
pubmed: 25483847
N Engl J Med. 2015 Mar 26;372(13):1193-203
pubmed: 25692915
Biomark Med. 2015;9(3):199-207
pubmed: 25731207
Exp Clin Endocrinol Diabetes. 2015 May;123(5):267-71
pubmed: 25853704
Ophthalmology. 2015 Jul;122(7):1395-401
pubmed: 25870079
BMC Endocr Disord. 2015 Mar 02;15:9
pubmed: 25887236
J Diabetes Res. 2015;2015:582060
pubmed: 26137497
Ann Hematol. 2015 Nov;94(11):1875-83
pubmed: 26223359
Int J Environ Res Public Health. 2015 Aug 21;12(8):10009-19
pubmed: 26308022
Clin Nephrol. 2016 Apr;85(4):199-208
pubmed: 26521887
Tumour Biol. 2016 Apr;37(4):5285-93
pubmed: 26561466
Eur Urol. 2016 Aug;70(2):358-64
pubmed: 26924770
Neuroimmunomodulation. 2016;23(2):67-74
pubmed: 26926300
Surv Ophthalmol. 2016 Nov - Dec;61(6):759-768
pubmed: 27045225
J Cancer. 2016 Feb 20;7(5):538-45
pubmed: 27053952
Stroke. 2016 Jun;47(6):1654-7
pubmed: 27165957
Ther Adv Med Oncol. 2016 May;8(3):160-7
pubmed: 27239234
Int J Cardiol. 2016 Nov 15;223:444-449
pubmed: 27544602
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
Mediators Inflamm. 2017;2017:9327136
pubmed: 28316378
Medicine (Baltimore). 2017 Apr;96(16):e6459
pubmed: 28422835
Adv Ther. 2017 Jun;34(6):1270-1282
pubmed: 28484955
Am J Cardiol. 2017 Sep 15;120(6):911-916
pubmed: 28779870
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
Int J Ophthalmol. 2017 Nov 18;10(11):1716-1721
pubmed: 29181316